| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_916517558eeccc457cc78a7ab28fc97e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-24143 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-2474
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5759
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2264
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2013 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate |
2021-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c3110c478ddaed3f80a2d4008826fb2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61a5d77a10163d8dc067124a2efe763f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61ef81b6e63f39c606bbba4be66901ff |
| publicationDate |
2022-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2022109133-A1 |
| titleOfInvention |
Oncolytic immunotherapy by tumor micro-environment remodeling |
| abstract |
The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses. |
| priorityDate |
2020-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |